-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the context of the changing medical environment, the flow of personnel has become more and more obvious
.
According to industry statistics, a total of 329 corporate executives will resign in 2021, and in 2022, personnel adjustments will still be frequent.
In January alone, nearly 30 pharmaceutical executives resigned, including many positions such as chairman, president, and deputy general manager.
.
For example, on February 10, Sihuan Bio released an announcement.
The board of directors of the company received a written resignation report from Mr.
Qian Guoshuang, an independent director of the company.
Mr.
Qian Guoshuang applied for his resignation as an independent director and member of the nomination committee of the ninth board of directors of the company due to personal reasons.
.
After his resignation, Mr.
Qian Guoshuang no longer holds any position in the company
.
On January 29, Nanhua Biotech announced that Mr.
Chen Yong had applied to resign as the secretary of the board of directors due to work arrangements
.
After Mr.
Chen Yong resigned from the above-mentioned positions, he still served as the deputy general manager of the company
.
On January 28, Garden Biology announced that Mr.
Chen Yi, the company's deputy general manager, had recently applied to the company's board of directors to resign as the company's deputy general manager because he had reached the retirement age
.
After Mr.
Chen Yi resigned as the deputy general manager of the company, he continued to hold other positions in the company
.
On the same day, China Resources Pharma announced that Han Yuewei would no longer serve as its director, chairman and legal representative, and Zhao Bingxiang would no longer serve as a director; Bai Xiaosong was appointed as a director, as well as chairman and legal representative, and Tao Ran was appointed as a director
.
At the same time, Bai Xiaosong was appointed as the general manager
.
On January 27, Boji Pharmaceutical announced that Ms.
Lu Xiaohua applied to resign as a supervisor of the company due to personal reasons.
After her resignation, Ms.
Lu Xiaohua still served as the deputy director of internal audit in the company
.
According to relevant regulations, Ms.
Lu Xiaohua will continue to perform her supervisory duties in accordance with relevant regulations before new supervisors are elected at the general meeting
.
On January 26, Weiming Pharmaceutical announced that the board of directors of the company recently received written resignation reports submitted by Mr.
Wang Lijun, Ms.
Zhang Yinuo, Ms.
Lai Wenbo and Ms.
Yang Yichen.
The above-mentioned personnel all resigned due to personal reasons
.
On the same day, Qizheng Tibetan Medicine announced that Mr.
Chen Weiwu had applied for his resignation as the general manager of the company's R&D center due to work needs. .
After his resignation, Mr.
Chen Weiwu will serve as the chief scientist of the company
.
For another example, Dong’e Ejiao announced on January 10, 2022 that Han Yuewei had applied to resign as chairman and director of the tenth session of the board of directors due to job changes, and also resigned as chairman of the strategy committee of the tenth session of the board of directors
.
After resigning, Han Yuewei no longer holds any position in Dong'e Ejiao
.
Gao Dengfeng, the president and legal representative of Dong’e Ejiao, also applied for resignation on the same day.
Due to the change of job content, Gao Dengfeng applied for resignation from the above two positions
.
After his resignation, Gao Dengfeng will continue to serve as a director of the tenth board of directors
.
Of course, some people leave and some people take office
.
For example, AstraZeneca's business adjustment is relatively busy.
It was reported on January 20 that from March 1, 2022, Chen Kangwei, the current general manager of AstraZeneca China Taiwan region, will be appointed as the general manager of AstraZeneca China Oncology Division.
Overall responsibility for AstraZeneca's oncology business in China
.
Not long ago, Yin Min, the former head of AstraZeneca's China Oncology Division, and Wang Dong, the former head of the retail division, announced their resignations
.
After the restructuring of Pfizer China in China at the end of 2021, appropriate personnel adjustments have also been made this year
.
In January, Pfizer successively announced the general managers and heads of other divisions of six independent divisions except rare diseases and broad markets, namely: Wang Yiqin, general manager of the tumor division, Li Jinhui, general manager of the hospital emergency division, vaccines.
Zhang Lingyan, general manager of the business unit, Dai Wenjie, general manager of the inflammation and immunity business unit, Qian Yun, head of market access, and Niu Yanlai, head of hospital access and strategic cooperation
.
.
According to industry statistics, a total of 329 corporate executives will resign in 2021, and in 2022, personnel adjustments will still be frequent.
In January alone, nearly 30 pharmaceutical executives resigned, including many positions such as chairman, president, and deputy general manager.
.
For example, on February 10, Sihuan Bio released an announcement.
The board of directors of the company received a written resignation report from Mr.
Qian Guoshuang, an independent director of the company.
Mr.
Qian Guoshuang applied for his resignation as an independent director and member of the nomination committee of the ninth board of directors of the company due to personal reasons.
.
After his resignation, Mr.
Qian Guoshuang no longer holds any position in the company
.
On January 29, Nanhua Biotech announced that Mr.
Chen Yong had applied to resign as the secretary of the board of directors due to work arrangements
.
After Mr.
Chen Yong resigned from the above-mentioned positions, he still served as the deputy general manager of the company
.
On January 28, Garden Biology announced that Mr.
Chen Yi, the company's deputy general manager, had recently applied to the company's board of directors to resign as the company's deputy general manager because he had reached the retirement age
.
After Mr.
Chen Yi resigned as the deputy general manager of the company, he continued to hold other positions in the company
.
On the same day, China Resources Pharma announced that Han Yuewei would no longer serve as its director, chairman and legal representative, and Zhao Bingxiang would no longer serve as a director; Bai Xiaosong was appointed as a director, as well as chairman and legal representative, and Tao Ran was appointed as a director
.
At the same time, Bai Xiaosong was appointed as the general manager
.
On January 27, Boji Pharmaceutical announced that Ms.
Lu Xiaohua applied to resign as a supervisor of the company due to personal reasons.
After her resignation, Ms.
Lu Xiaohua still served as the deputy director of internal audit in the company
.
According to relevant regulations, Ms.
Lu Xiaohua will continue to perform her supervisory duties in accordance with relevant regulations before new supervisors are elected at the general meeting
.
On January 26, Weiming Pharmaceutical announced that the board of directors of the company recently received written resignation reports submitted by Mr.
Wang Lijun, Ms.
Zhang Yinuo, Ms.
Lai Wenbo and Ms.
Yang Yichen.
The above-mentioned personnel all resigned due to personal reasons
.
On the same day, Qizheng Tibetan Medicine announced that Mr.
Chen Weiwu had applied for his resignation as the general manager of the company's R&D center due to work needs. .
After his resignation, Mr.
Chen Weiwu will serve as the chief scientist of the company
.
For another example, Dong’e Ejiao announced on January 10, 2022 that Han Yuewei had applied to resign as chairman and director of the tenth session of the board of directors due to job changes, and also resigned as chairman of the strategy committee of the tenth session of the board of directors
.
After resigning, Han Yuewei no longer holds any position in Dong'e Ejiao
.
Gao Dengfeng, the president and legal representative of Dong’e Ejiao, also applied for resignation on the same day.
Due to the change of job content, Gao Dengfeng applied for resignation from the above two positions
.
After his resignation, Gao Dengfeng will continue to serve as a director of the tenth board of directors
.
Of course, some people leave and some people take office
.
For example, AstraZeneca's business adjustment is relatively busy.
It was reported on January 20 that from March 1, 2022, Chen Kangwei, the current general manager of AstraZeneca China Taiwan region, will be appointed as the general manager of AstraZeneca China Oncology Division.
Overall responsibility for AstraZeneca's oncology business in China
.
Not long ago, Yin Min, the former head of AstraZeneca's China Oncology Division, and Wang Dong, the former head of the retail division, announced their resignations
.
After the restructuring of Pfizer China in China at the end of 2021, appropriate personnel adjustments have also been made this year
.
In January, Pfizer successively announced the general managers and heads of other divisions of six independent divisions except rare diseases and broad markets, namely: Wang Yiqin, general manager of the tumor division, Li Jinhui, general manager of the hospital emergency division, vaccines.
Zhang Lingyan, general manager of the business unit, Dai Wenjie, general manager of the inflammation and immunity business unit, Qian Yun, head of market access, and Niu Yanlai, head of hospital access and strategic cooperation
.
